An Australian medical technology company founded by a genetics expert plans to bypass the ASX and list on the Nasdaq in the coming months in an attempt to carve out a slice of the US$9 billion ($13.6 billion) American IVF market.
Nick Murphy founded GenEmbryomics in Melbourne in 2019. He has developed a test that allows IVF patients to screen embryos for more than 2500 genetic disorders that are life-threatening or cause severe disabilities.
Loading...
Tess Bennett is a technology reporter with The Australian Financial Review, based in the Brisbane newsroom. She was previously the work & careers reporter. Connect with Tess on Twitter. Email Tess at tess.bennett@afr.com
